REFERENCES
- Aoki K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001; 39: 1815–1820
- Aoki K. R. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 2002; 40: 923–928
- Costa J., Espirito-Santo C., Borges A., Ferreira J. J., Coelho M., Moore P., Sampaio C. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev 2005, CD003633.
- Dutton J. J. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv. Ophthalmol 1996; 41: 51–65
- Ghosh B., Das S. K. Botulinum toxin: a dreaded toxin for use in human being. J. Indian Med. Assoc 2002; 100: 607–608, 610–602, 614.
- Huang W., Foster J. A., Rogachefsky A. S. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol 2000; 43: 249–259
- Kang B. H., Son H.-Y., Ha C. S., Lee H.-S., Song S.-W. Reference values of hematology and serum chemistry in Ktc:Sprague-Dawley rats. Korean J. Lab. Anim. Sci 1995; 11: 141–145
- McLellan K., Das R. E., Ekong T. A., Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996; 34: 975–985
- Montecucco C., Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol 1994; 13: 1–8
- Nolan K. W., Cole L. L., Liptak G. S. Use of botulinum toxin type A in children with cerebral palsy. Phys. Ther 2006; 86: 573–584
- Rosales R. L., Bigalke H., Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol 2006; 13(Suppl 1)2–10
- Yohio T. Biological reference data book on experimental animals. Soft Science, Inc. 1989, (Tokyo).
- Zesiewicz T. A., Stamey W., Sullivan K. L., Hauser R. A. Botulinum toxin A for the treatment of cervical dystonia. Expert Opin. Pharmacother 2004; 5: 2017–2024